Major risk factors for infections in CLL and s... - CLL Support
Major risk factors for infections in CLL and strategies to mitigate risk
You need to be a member of this community to see this post.
9 Replies
You need to be a member of this community to see hidden responses.
Not what you're looking for?
You may also like...
Early results of the Pirtobrutinib, Obinituzumab, Venetoclax trial I'm on have just been published
Dr. Jain of M.D. Anderson has published an oral abstract in advance of the European Hematological...
Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia
Abstract report in New England Journal of Medicine Published February 5, 2025
No real new...
Acalabrutinib exhibits comparable efficacy, superior safety to ibrutinib for CLL (finally!)
Positive high-level results from the ELEVATE-RR Phase III trial showed AstraZeneca’s Calquence...
Adding Venetoclax to Obinutuzumab Prolongs Progression-Free Survival in Previously Untreated CLL
Dated 1st September 2019
In a phase III trial of patients with previously untreated CLL...
Incorrect Interpretation of BTKis & Incidence of SPM
Related to the earlier post by @[1715668]; Bond et al. were studying whether BTKis could decrease...
Related Posts
- Time-to-progression after front-line FCR for CLL: a retrospective, multicohort study
CLL Medications and Corona Virus
COVID risk to CLL patients with the reopening of schools
COVID-19 among fit patients with CLL treated with venetoclax-based combinations- Dr. Shadman on Fixed Durations of Treatment in CLL
